HE EXPRESSION of the globin genes is regulated during
T ontogeny. In humans, globin production is characterized by two major "switches."'*2 The production of embryonic hemoglobins (Hb) switches after the first 2 months ofgestation into the production of the two types of fetal Hb (HbF) and then again, before birth, into the adult Hb (HbA and HbA2).
More than 50 mutations have been described that increase HbF synthesis in postnatal life.2 Many reflect deletion of a portion of the globin gene cluster, whereas others result from point mutations within or outside of the cluster. An increase in HbF is frequently observed in inherited blood disorders such as 0-hemoglobinopathies-the sickle cell anemia and @-thalassemia syndrome~~-~-and may be acquired, for example, in juvenile myelogenous leukemia" or during acute erythropoietic ~tress.~ In both sickle cell anemia and 0-thalassemia, an increase in HbF ameliorates the clinical symptoms of the underlying disease6 as HbF-containing red blood cells (F cells) have both lower concentrations of sickle Hb (HbS), and HbF directly inhibits polymerization of HbS, accounting for the lower propensity of such cells to form intracellular polymer and cause pathophysiologic consequence^.^.'
Recently, several pharmacologic agents, such as cell cycledependent cytotoxic drugs, have been used to stimulate HbF normal individuals 4 days following their exposure to erythropoietin (EPO), 100 Fmol/L HU caused a 1.3-to 3.5-fold increase in the proportion of HbF, from 0.4% to 5.2% (mean 1.6) in untreated to 1.5% to 8.2% (mean 3.1) in HU-treated cultures and a 45% f 10% increase in MCH but only a 25% f 7% decrease in cell number on day 13 . Cultures of cells derived from five patients with sickle cell anemia have shown a twofold to fivefold increase in the percentage of Hb F following addition of HU while four patients with @-thalassemia showed a 1.3-to 6.2-fold increase. We believe that this primary cell culture procedure should prove useful in studying the cellular and molecular mechanisms of pharmacologic induction of HbF and might provide a valuable predictive assay system for evaluation of the response of individual patients with hemoglobinopathies to HU and similar agents. This is a US government work. There are no restrictions on its use. synthesis in vivo. The initial studies involved treatment of baboons,* or patients with either P-thalassemia' or sickle cell anemialo," with 5'-azacytidine. The animals and the patients responded with considerable stimulation of HbF production. Because of concerns about the potential carcinogenicity of 5'-azacytidine," in the last 5 years most animal and human studies have concentrated on hydroxyurea (HU) and other drugs recently observed to perturb the normal ontogenetic switch in hemoglobin expre~sion.'~-'~ The complexity of the in vivo erythroid marrow makes it difficult to study the mechanism(s) underlying the effect of these drugs. Two culture systems have been used for these studies: in vitro established immortalized cell lines that can be induced to express some erythroid characteristic^,"^'^ and primary cultures of erythroid progenitors derived from peripheral blood or bone marrow (BM) that develop as colonies in semisolid medium supplemented with erythropoietin (EPO).'' Although cell lines serve as convenient experimental models, they may not represent all aspects of erythropoiesis, eg, responsiveness to EPO or production of adult Hb,20 perhaps because of their neoplastic nature. In addition, establishment of such lines is a rare event and normal cells and cells from most patients cannot be immortalized at all. In contrast, primary cultures of erythroid cells can be established from most normal individuals and patients and their growth in vitro represents more closely the in vivo situation. Several agents, such as 5'-azacytidine and butyrate, have been shown to increase Hb F production in such cultures derived from normal peripheral blood, BM, or cord blood, and in cultures derived from patients with sickle cell anemia and P-thalas~e m i a .~' -~~ However, these studies failed to demonstrate any consistent effects of HU on cultured erythroid cells.2'.22
We have recently described a novel two-phase liquid culture procedure for growing human erythroid cells in The two phases are: (1) An EPO-independent phase, in which the cells are first cultured in the presence of a combination of growth factors, but not of EPO. During this phase early erythroid committed progenitors, burst-forming units (BFU- For personal use only. on November 11, 2017. by guest www.bloodjournal.org From e), proliferate and differentiate into colony-forming unit (CFU-e)-like progenitors. (2) The latter cells are then cultured in an EPO-supplemented medium, in which the CFU-e-like progenitors continue to proliferate and mature into orthochromatic normoblasts and then enucleated erythrocytes. This procedure yields large (up to 5 X lo*), pure (95% to 98%) populations of erythroid cells, which allow detailed study of normal and pathologic erythroid maturation and the analysis of the effects of various pharmacologic agents in primary cultures of cells derived from the relevant patients.
In the present study, we investigated the effect of HU in cultures derived from normal donors and patients with sickle cell anemia and P-thalassemia. The results indicated that the hematologic effects demonstrated in patients undergoing treatment with HU,"-I6 and especially the increase in Hb F, could be recapitulated in vitro.
MATERIALS AND METHODS

Erythroid cell cultures.
The two-phase liquid culture procedure has been previously described in
In short, peripheral blood mononuclear cells obtained from normal volunteers or patients with hemoglobinopathies were isolated by centrifugation on a gradient of Ficoll-Hypaque and seeded at a density of 5 X lo6 cells/mL in aminimal essential medium supplemented with 10% fetal calf serum (FCS) (both from GIBCO, Grand Island, NY), 1 pg/mL cyclosporin A (Sandoz, Basel, Switzerland), and 10% conditioned medium collected from cultures of the 5637 bladder-carcinoma cell line. 26 The cultures were incubated at 37°C in an atmosphere of 5% COz in air with extra humidity.
After a 5-day incubation in this phase I culture, the nonadherent cells were harvested, washed, and recultured in fresh medium composed of a-medium, 30% FCS, 1% deionized bovine serum albumin, 1 X mol/L dexamethasone, and 1 U/mL human recombinant EPO (Cilag AG, Schaufiausen, Switzerland).
After a 4-day incubation in phase 11, lymphocytes were removed as follows: the cells were harvested, spun down, the medium saved, and the cells layered on a Percoll (Sigma, St Louis, MO) solution (density = 1.0585 g/mL) and centrifuged at 1,OOOg for 20 minutes at room temperature. The upper layer, containing the proerythroblasts, was collected, resuspended in the saved medium, and incubation continued. These cultures yielded up to 4 X IO6 erythroid cells (normoblasts) per milliliter of blood.
Viable cell count was performed using the Trypan Blue exclusion technique. The number of Hb-containing cells was determined using the benzidine-Ha procedure?' Erythroid cell maturation was assessed morphologically by preparing cytocentrifuge slides (Shandon, Cheshire, UK) stained with alkaline benzidine and Giemsa (Fluka, Buchs, Switzerland).
Peripheral blood or cultured cells were washed three times with phosphate-buffered saline and the pellet was lysed by resuspending the cells in double distilled water and incubating on ice for 5 to 10 minutes. After spinning for I minute in a microcentrifuge, the supematant was collected and stored at 4°C.
Alkali denaturation procedure for determination of Hb F. Ninety microliters of the tested hemolysate was added to 10 pL of human immune globulin (5 g/dL; Miles Inc, Cutter Biological, Elkhart, IN). Then, 7 pL of 1.2 N NaOH was added, and the mixture vortexed. After exactly 2 minutes, 70 pL of a saturated solution of ammonium sulfate was added, mixed, incubated at room temperature for 5 minutes, and spun for 1 minute in a microcentrifuge. The supematant, which contains Hb F only, was collected and saved for spectrophotometric Hb determination. For total Hb, 10 pL of lysate was diluted mol/L 2-mercaptoethanol, 1.5 mmol/Lglutamine, 1 X Preparation of lysates. 
High performance liquid chromatography (HPLC).
RESULTS
Addition of HU, at concentrations of 25 to 400 pmol/L, to cultures of cells derived from the peripheral blood of normal donors as well as from patients with either sickle cell anemia or &thalassemia during the first phase of the culture or during the first 4 days of the second phase (phase 11) completely ablated erythroid cell development (data not shown). Adding HU at later stages was compatible with cell survival and differentiation. Figure 1 depicts the effects of addition of HU on days 4, 7, and 10 of phase 11, following exposure to EPO, on erythroid cell numbers (Fig lA) , Hb per cell (Fig   lB) , and the proportion of HbF (Fig 1C) . The results indicate that all these parameters were dependent on the HU dose and time of addition to the cultures. At concentrations of 400 pmol/L, HU decreased cell yield by 90% when added on day 4 of phase 11, but had only a moderate effect when added on days 7 or IO. At concentrations of 200 pmol/L and below, although cell number decreased, no apparent toxicity was evident by the Trypan Blue exclusion test. These results suggest that HU affects cell yield in these cultures mainly through its cytostatic effect by blocking cell proliferation.
HU at concentrations of 100 pmol/L and higher significantly increased both the total amount of Hb synthesized per cell (mean corpuscular hemoglobin [MCH]), which increased from 20 pg to 33 pg/cell, and the proportion of HbF, which increased from 1.2% in untreated cells up to 4.8% in cells treated on day 4 of phase I1 with 400 pmol/L HU. The increase in the percent HbF could not by itself account for the increase in MCH. Thus, treatment of the cells with HU was also associated with increased levels of adult Hb. Similar results were obtained in more than six independent experiments using cells obtained from different donors. With 100 pmol/L HU, the MCH increased by 38% to 65% (mean 45%) and the proportion of HbF increased 1.3-to 3.5-fold (mean 2.7) (Fig 2) . The results were similar (+IO%) whether the percent HbF was measured by the alkali-denaturation-TMB assay or by cation exchange HPLC.
Analyzing the kinetics of accumulation of Hb-containing cells in the cultures by staining with the benzidine reagent indicated that 4, 7, 10, and 13 days after exposure to EPO, 37%, 75%, 94%, and 96% of the cells, respectively, were benzidine reactive, similar to those obtained in a previous Treatment with HU, at any concentration used in this study, did not significantly change the kinetics (data not shown). Because HU may be labile under the culture conditions used, we analyzed the effect of multiple additions of HU on the percent HbF. Adding HU only on day 7 of phase I1 resulted in a 2.4-fold increase in the percent HbF when the cells were harvested and analyzed on day 13. If HU was added repeatedly on days 7 and 9, or on days 7, 9, and 11, the percent HbF increased 3-and 3.4-fold, respectively. Thus, multiple additions result in a greater increment in HbF, suggesting that HU stability may influence results of such experiments.
Exposure to HU was associated with a significant increase in cell size. This effect was evident as early as the first day after its addition to 4-day phase I1 cultures, and was most prominent on the second day. Erythroid cell maturation in vivo is associated with a decrease in cell size.29 This was recapitulated in this system in vitro, both in untreated and HU-treated cultures. Nevertheless, when analyzed on day 13, when most of the cells reached the orthochromatic normoblast stage, HU-treated cells were still larger than control cells. This is shown in Fig 3, where normal erythroid cells were exposed to 100 fimol/L HU on day 7 of phase I1 and analyzed on day 13 for size by measuring forward light scattering (FS) by flow cytometry. While the untreated population showed a unimodal distribution with a mean at channel 341 (on a linear scale of 1,024 channels), HU-treated cells showed a bimodal distribution caused by the presence of two distinctive subpopulations. The subpopulation with the larger cells comprised about 70% of the total population, and had a mean FS at channel 549, as compared with a mean channel of 305 of the small cell subpopulation. Only 10% of the untreated cells were within the boundaries of the large cell subpopulation of the HU-treated cells. The forward light-scattering property of cells is mainly a function of cell size3'; therefore, the results indicate a I .6-fold difference in size between the large cell population in the treated as compared with the bulk of cells in the untreated cultures, but also show the existence of two populations with 1.8-fold difference in size, in the treated culture. These differences were easily discerned by observing unstained cells using an inverted microscope or Giemsa-stained smears using a regular light microscope. In addition to normal cells, the effect of HU was studied in cultures derived from patients with either sickle cell anemia or P-thalassemia. The HPLC chromatograph of one sickle cell anemia patient, homozygous for the SS genotype, is demonstrated in Fig 4. In this patient, the HbF increased from 5.2% in the untreated to 11.3% in the HU-treated cultures. Analysis of four additional patients indicated a 2.2-to 5.1-fold increase in the proportion of HbF, with a mean of 3.2-fold increase (Fig 2) . For Cells derived from four patients with j3-thalassemia major were cultured in the two-phase liquid culture system. HU (100 mmol/L) was added to day 7 of phase II and cells were harvested on day 13. The patients were from the Israeli Kurdish population whose molecular characterization has been previously rep~rted.~'"' Benzidine-positive cells. The results in cultures of cells derived from patients with P-thalassemia are summarized in Table 1 . As noted with normal and sickle cells, cells from the P-thalassemia patients, when incubated in HU, also showed a decreased cell number due to inhibition of cell proliferation, but increased MCH, as well as elevation in the proportion of Hb F (varying from 1.3-to 6.2-fold) (Fig 2) .
DISCUSSION
In the present study, we report that several HU-mediated effects on erythroid cells, previously demonstrated in vivo after treatment of patients with sickle cell anemia,13-16 could be recapitulated in cultures of cells derived from patients with hemoglobinopathies as well as from normal donors. HU was found to cause: (1) an increase in the proportion of H b F (2) an increase in cell size (mean cell volume [MCV]); (3) an increase in the cellular Hb content (MCH), and (4) an inhibition of cell proliferation.
All of these effects were dose and time dependent; no change was found in cell size and hemoglobin phenotype at concentrations that did not affect cell proliferation (25 pmol/ L and lower). Maximal effect was noted at concentrations of 400 pmol/L, when proliferation was completely blocked, although significant changes were also observed at 100 to 200 pmol/L, when cell proliferation was only partially affected. The latter concentrations did not affect cell viability, as determined by staining with Trypan Blue.
The failure of previous studies to show HU-stimulation of HbF production in primary cultures2'*22 may be related to the fact that by using the standard cell cloning method in semisolid medium, cells with abnormally high levels of HbF develop. Such cells may have already used their full potential for HbF production and therefore do not respond to additional stimulation, eg, treatment with HU. In contrast, the Hb pattern produced in the two-phase liquid culture system used in the present study (Fig IC, Fig 2, Fig 4, and Table 1 ) was similar to that found in vivo, either in normal individuals or in patients with elevated HbF levels. In addition, the twophase liquid culture system yielded pure and large populations of erythroid cells that allowed direct study of the cells with respect to maturation and Hb accumulation under conditions where cell proliferation was inhibited. This is technically impossible in the colony method that depends on indirect analysis.
Our results suggest that HU affects Hb phenotype by direct interaction with relatively late erythroid precursors that are already engaged in Hb production. The results also suggest that the effect required neither the mediation of accessory cells (eg, macrophages, lymphocytes, or stromal cells), nor specific growth factors, eg, granulocyte-macrophage colonystimulating factor (GM-CSF), that has been reported to enhance HbF production in the progeny of early erythroid progenitor~.~'
The mechanisms involved in the HU-mediated changes are still unclear. They may involve a selection of a minor, pre-existing, subpopulation of F cells that has a growth and/ or survival advantage. This mechanism may be particularly effective for cells derived from patients with P-hemoglobinopathies, where F cells may be resistant to "ineffective erythropoiesis," ie, premature death of the erythroid precursors due to their abnormal Hb ~o n t e n t .~ An alternative mechanism could involve stimulation of HbF in all or the majority of the population by direct induction, eg, by removing DNAbinding, negative trans-acting proteins from the y-promoter region, or indirectly, eg, by modifying the cell cycle or growth kinetics. We believe that the two-phase liquid culture system will be a valuable tool for studying these mechanisms on the cellular, biochemical, and molecular levels. Understanding of the mechanism will provide the rationale for a logical search for agents with HbF-stimulating activity and limit the trial and error approach. The effects of HU were reproduced in cultures of cells derived from normal individuals who had low levels of HbF, as well as from patients with hemoglobinopathies who had elevated levels of HbF. Heterogeneity was found in the response among the normal individuals and patients studied. For example, one thalassemic patient responded with almost no increase in HbF, whereas three other patients showed a 2.7-to 6.2-fold increase. Increased HbF production in vivo was found in about 75% of the HU-treated sickle cell anemia patients. '3-'s No molecular, biochemical, cellular, or clinical parameter was found to predict the outcome of the treatment.
In an ongoing study, we are comparing the response to HU of cultured cells derived from patients with sickle cell anemia For personal use only. on November 11, 2017. by guest www.bloodjournal.org From to the patient's response to treatment to see if it is possible by testing cultures derived from the patient's peripheral blood to predict response in vivo.
